Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients

Transplantation

Volumn 92, Issue 9, 2011, Pages 1063-1068

  Lisboa, Luiz F ^a   Preiksaitis, Jutta K ^a   Humar, Atul ^a   Kumar, Deepali ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ganciclovir; Hybrid strategy; Preemptive therapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; THERAPY EFFECT; TREATMENT DURATION; VIREMIA; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 80055015760     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822fa4b7     Document Type: Review

References (16)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
2. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S78.
3. Boillat Blanco N, Pascual M, Venetz JP, et al. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011; 91: 251.
4. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
5. Gerna G, Lilleri D, Callegaro A, et al. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 2008; 86: 163.
6. Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009; 87: 1318.
7. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
8. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
9. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
10. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761.
11. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032.
12. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.AmJ Transplant 2005; 5: 1462.
13. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
14. Pang XL, Chui L, Fenton J, et al. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol 2003; 41: 3167.
15. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305.
16. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829.